Newsletter Tool

To view this email as a web page, click here

Today's Rundown

With expanded FDA nod, Regeneron's COVID-19 antibody drug can help the immunocompromised
U.S. sent Mexico and Canada AstraZeneca COVID-19 vaccines before fully vetting production site: report
53 health systems requiring mandatory COVID-19 vaccines for their workforces
As Veklury's sales slide, Gilead hopes for a quicker rebound from Biktarvy, other HIV drugs
COVID-19 tracker: CDC warns 'war has changed' with Delta variant; Japan to resume AZ jabs as cases climb
Fierce Pharma Asia—AstraZeneca's China growth; Takeda's $3.5B neuro pact; Biocon, Viatris' historic biosimilar nod

Featured Story

With expanded FDA nod, Regeneron's COVID-19 antibody drug can help the immunocompromised

By Kevin Dunleavy

The FDA has expanded its EUA for Regeneron's COVID-19 drug as a preventative therapy for those who have been exposed to the disease and who are at high risk to progress to a severe case.

U.S. sent Mexico and Canada AstraZeneca COVID-19 vaccines before fully vetting production site: report

By Kevin Dunleavy

The U.S. sent AstraZeneca COVID-19 vaccines to Mexico and Canada even though it had yet to sanction the plant where they were manufactured, Emergent's troubled facility in Baltimore.

53 health systems requiring mandatory COVID-19 vaccines for their workforces

By Dave Muoio

COVID-19 vaccination as a condition of employment has picked up the support of numerous industry and professional organizations. More health systems are taking a hard stance.

As Veklury's sales slide, Gilead hopes for a quicker rebound from Biktarvy, other HIV drugs

By Kevin Dunleavy

As the coronavirus pandemic subsides, so do the sales for Gilead's Veklury. The company now hopes for a corresponding improvement in the sales of its formidable HIV treatments.

COVID-19 tracker: CDC warns 'war has changed' with Delta variant; Japan to resume AZ jabs as cases climb

By Noah Higgins-Dunn,Kevin Dunleavy,Fraiser Kansteiner

The CDC warned in internal presentations that the war against COVID-19 has changed because of the rapidly spreading Delta variant, the Washington Post reports. Japan will resume using AstraZeneca's jab following safety concerns as Tokyo reports record infections. And more headlines.

Fierce Pharma Asia—AstraZeneca's China growth; Takeda's $3.5B neuro pact; Biocon, Viatris' historic biosimilar nod

By Angus Liu

AstraZeneca expects slower growth from its China business moving forward. Takeda signed a neurodegenerative diseases R&D pact with PeptiDream worth up to $3.5 billion. Biocon and Viatris won the first FDA interchangeable biosimilar tag for their copy of Sanofi's Lantus. And more.

COVID-19 Tracker

Featured Story

With expanded FDA nod, Regeneron's COVID-19 antibody drug can help the immunocompromised

Top Stories

U.S. sent Mexico and Canada AstraZeneca COVID-19 vaccines before fully vetting production site: report

53 health systems requiring mandatory COVID-19 vaccines for their workforces

As Veklury's sales slide, Gilead hopes for a quicker rebound from Biktarvy, other HIV drugs

COVID-19 tracker: CDC warns 'war has changed' with Delta variant; Japan to resume AZ jabs as cases climb

Fierce Pharma Asia—AstraZeneca's China growth; Takeda's $3.5B neuro pact; Biocon, Viatris' historic biosimilar nod